Cartherics to present at prestigious oncology conference in France
By Christine Filippis / March 3, 2023
Cartherics is pleased to announce that Dr Vera Evtimov, Project Manager and Principal Scientist, will be presenting her work in...
Read More
Cartherics to present at Australia Biologics 2023
By Christine Filippis / February 28, 2023
Cartherics is pleased to announce that Dr Madeline Cao, Research Fellow, will be presenting at Australia Biologics 2023 at Crown...
Read More
Peter MacCallum Cancer Centre and Cartherics Announce Collaboration to Develop Autologous CAR-T Cell Therapy for Ovarian Cancer
By Christine Filippis / February 27, 2023
Melbourne, Victoria, Australia 27 February 2023 Peter MacCallum Cancer Centre (“Peter Mac”) and Cartherics Pty Ltd (“Cartherics”) announced today they...
Read More
Cartherics is ‘Turning Teal’ this February in support of ovarian cancer
By Christine Filippis / February 22, 2023
Cartherics is delighted to be hosting a Teal Tea this February to raise awareness and funds for people affected by...
Read More
Cartherics celebrates PhD student’s success
By Christine Filippis / February 6, 2023
Cartherics is delighted to announce that Saleh Almasabi has successfully completed his PhD Candidature. Saleh’s research thesis, ‘The role of...
Read More
CGTLive Interview: New Frontiers in Allogeneic Cell Therapy
By Christine Filippis / January 20, 2023
Cartherics’ CEO, Professor Alan Trounson, was recently interviewed by CGTLive, to discuss the company’s development of NK cell, T-cell and...
Read More
Cartherics granted first patent in China for multiple development candidates
By Christine Filippis / January 9, 2023
Melbourne, Australia, 09 January 2023 – Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the treatment...
Read More
Cartherics to Present at Biotech Showcase™ 2023
By Christine Filippis / December 22, 2022
Cartherics to Present at Biotech Showcase™ 2023 Dr Ian Nisbet will provide a presentation on Cartherics’ technology and development program...
Read More
Message from the CEO – December 2022
By Christine Filippis / December 14, 2022
This year has been an exciting and productive one for Cartherics. We opened our new and impressive research and development...
Read More
Breaking the Mould: Building a Research-Based Biotech Company in Australia from Scratch
By Christine Filippis / December 7, 2022
Ian Nisbet and Alan Trounson, AO Australia is a very challenging environment for early-stage biotechnology companies. Risk capital is hard...
Read More
Peter MacCallum Cancer Centre and Cartherics Announce Collaboration to Develop Autologous CAR-T Cell Therapy for Cutaneous T-Cell Lymphoma
By Christine Filippis / November 8, 2022
Melbourne, Victoria, Australia - 08 November 2022 The Peter MacCallum Cancer Centre (“Peter Mac”) and Cartherics Pty Ltd (“Cartherics”) announced...
Read More
Cartherics is ‘Frocking Up’ this month in support of ovarian cancer research
By Christine Filippis / October 17, 2022
Cartherics is delighted to be participating in Frocktober – Australia’s most fashionable month-long fundraiser to raise awareness and funds for...
Read More
Cartherics unveils new $4M lab to develop cancer immunotherapy treatments in Victoria
By Christine Filippis / October 13, 2022
MELBOURNE, Australia, 13 October 2022 – Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, has...
Read More
Cartherics granted first US patent for multiple development candidates
By Christine Filippis / October 6, 2022
Melbourne, Australia, 06 October 2022 – Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, announced...
Read More
Cartherics-led Consortium Receives $5.4M Federal Funding for Cellular Immunotherapy Research into Ovarian and Gastric Cancers
By Christine Filippis / September 30, 2022
MELBOURNE, Australia, 27 September 2022 – Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, together...
Read More
